Legend Biotech (LEGN) shares soared 42.22% on Tuesday, closing at $36.28, as investors reacted to early but promising clinical data for the company's experimental in vivo CAR-T therapy, LB2501. The stock continued to trade actively in Wednesday's session as the market digested the implications for the biotech's pipeline beyond its approved multiple myeloma drug Carvykti.
Phase 1 Data Shows Strong Response
The company announced initial results from a Phase 1 study of LB2501, its in vivo CAR-T treatment targeting relapsed or refractory B-cell non-Hodgkin lymphoma. As of April 1, 12 patients had been treated at two dose levels. In the higher-dose cohort, all six patients achieved an objective response, meaning their tumors shrank or disappeared, and five of those experienced a complete response with no detectable signs of cancer. All responses in the higher-dose group were ongoing at the data cutoff.
In vivo CAR-T therapy is designed to reprogram T cells inside the patient's body, potentially eliminating the need for the complex cell manufacturing and lymphodepleting chemotherapy required by traditional CAR-T approaches. Legend CEO Ying Huang called the results "an important step" for the field, adding that the approach could "simplify treatment delivery and expand access" to cell therapy.
Analyst Reactions and Price Target Boost
Oppenheimer analyst Kostas Biliouris described the data as showing a "potentially best-in-class profile" for in vivo CAR-T, according to Reuters, and suggested it could enhance Legend's appeal as an acquisition target. The Wall Street Journal quoted Biliouris calling the results a "best-case scenario."
UBS raised its price target on Legend to $49 from $31, maintaining a Buy rating. The bank said it now incorporates a market model for Legend's in vivo CAR-T program in non-Hodgkin lymphoma into its valuation. The revised target implies significant upside from the current trading level.
Upcoming Data and Market Context
The next major catalyst is imminent: Legend will present full LB2501 data in a late-breaking oral session at the European Hematology Association congress in Stockholm on June 14. This presentation will provide more detail on safety, durability of responses, and additional dose cohorts.
The enthusiasm for Legend's in vivo approach is part of a broader industry trend. AstraZeneca and Eli Lilly have both recently announced in vivo CAR-T deals, according to Reuters, signaling that major pharmaceutical companies are closely watching this technology as a potential solution to the cost and access limitations of traditional cell therapies.
Underlying Business Strength
Legend's commercial foundation remains solid. Carvykti, co-marketed with Johnson & Johnson, generated approximately $597 million in first-quarter net trade sales, a 62% increase year-over-year. The product is now available in 18 markets. Legend reported first-quarter revenue of $305.1 million, though it posted a net loss of $54.3 million. The company held $834.6 million in cash, cash equivalents, and time deposits as of March 31.
Risks to Consider
Despite the excitement, the data comes with important caveats. This is a Phase 1 study, and the high-dose results are based on just six patients with a median follow-up of only 2.2 months. Longer-term efficacy and safety data, additional dose information, or any regulatory feedback could temper the rally. Legend's own filings warn that expectations could shift on any surprise clinical or regulatory news.
For now, the market is re-evaluating Legend not just as a partner for Johnson & Johnson's Carvykti, but as one of the few publicly traded companies with early human data on a potentially simpler CAR-T approach. The next few weeks will be critical in determining whether this enthusiasm is sustainable.
